Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | Director | February 06, 2024 | February 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date February 06, 2024 · Filed February 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,709 |
Ending reported balance
After 2024-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-06 · Conversion · Acquired 39,259 · Balance 39,259 F1: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. Row 2 · 2024-02-06 · Conversion · Acquired 8,450 · Balance 47,709 F2: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-06 · Conversion · Disposed 83,333 · Balance 0 F1: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-06 · Conversion · Disposed 18,794 · Balance 0 F2: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.
F2: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2024 Filed Feb 7, 2024 16:35 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries C Preferred Stock · Derivative | 18,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002932 · form4-02072024_090224.xml · derivative · entry 4 Chen Po Yu (Jeff) · CIK 0002008609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. F2 · derivative.exercise_date: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. F2 · derivative.expiration_date: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 16:35 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries B Preferred Stock · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002932 · form4-02072024_090224.xml · derivative · entry 3 Chen Po Yu (Jeff) · CIK 0002008609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 16:35 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 8,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002932 · form4-02072024_090224.xml · nonDerivative · entry 2 Chen Po Yu (Jeff) · CIK 0002008609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 16:35 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 39,259 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002932 · form4-02072024_090224.xml · nonDerivative · entry 1 Chen Po Yu (Jeff) · CIK 0002008609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 16:43 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 1,540 | $11.88 Strike: $16.00 | $18,301.36 |
DisclosureSEC source: 0001415889-24-002563 · form4-02052024_090247.xml · derivative · entry 2 Chen Po Yu (Jeff) · CIK 0002008609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,540 Underlying: Common Stock · 1,540 shares Expires 2034-01-31 F3 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $18,333.50. F2 · derivative.exercise_date: 280 shares underlying the option shall vest on March 31, 2024, and 420 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 16:43 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 30,574 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002563 · form4-02052024_090247.xml · derivative · entry 1 Chen Po Yu (Jeff) · CIK 0002008609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,574 Underlying: Common Stock · 30,574 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on March 1, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.